Doubling Survival: New Hope for ER-Positive, HER2-Positive Metastatic Breast Cancer

The PATINA Trial: Highlighting the Importance of CDK 4/6 Inhibitors

For patients with metastatic breast cancer that is both estrogen receptor (ER) positive and HER2 positive, treatment has traditionally focused on maximizing HER2-targeted therapies. While chemotherapy, trastuzumab, and pertuzumab have been effective, the role of CDK 4/6 inhibitors was not fully understood until the PATINA trial.

The PATINA trial investigated the addition of palbociclib, a CDK 4/6 inhibitor, to endocrine therapy in patients with ER-positive, HER2-positive metastatic breast cancer after completing chemotherapy. The results were groundbreaking: progression-free survival (PFS) doubled from an average of 20 months to over 40 months!

Dr. Hassan Ghazal, Oncologist at King’s College Hospital Dubai, highlights the significance of this finding. “This trial revealed the critical importance of incorporating CDK 4/6 inhibitors into treatment regimens for these patients,” he explains. “It emphasizes that we need to pay attention not just to HER2-positive status but also to the ER status and optimize treatment accordingly.”

The PATINA trial findings are currently under review by the FDA, with approval anticipated soon. Dr. Ghazal believes that palbociclib, when combined with endocrine therapy and anti-HER2 treatments, will become the new standard of care for ER-positive, HER2-positive metastatic breast cancer.

This breakthrough represents a significant advance in personalized treatment strategies for breast cancer patients, offering hope for improved outcomes and quality of life.